UNITED
STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of report
(Date of earliest event reported): September 14, 2020
CHAMPIONS
ONCOLOGY, INC.
(Exact name of
registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-11504
|
|
52-1401755
|
|
(State or Other
Jurisdiction
|
|
(Commission File
Number)
|
|
(IRS Employer
|
|
of
Incorporation)
|
|
|
|
Identification
No.)
|
1 University
Plaza, Suite 307, Hackensack, New Jersey 07601
(Address of
Principal Executive Offices)
Registrant’s
telephone number, including area code: (201)
808-8400
N/A
(Former Name or
Former Address if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
|
|
|
|
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
|
|
|
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
|
|
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
|
|
|
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check
mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company o
If an emerging
growth company, indicate by check mark if the registrant has
elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. o
INFORMATION
TO BE INCLUDED IN THE REPORT
|
|
|
|
|
|
Item
2.02.
|
Results of
Operations and Financial Condition.
|
On September 14,
2020, Champions Oncology, Inc. (the “Company”) issued a press
release regarding the Company’s unaudited financial results for its
fiscal quarter ended July 31,
2020. A
copy of the Company’s press release is attached hereto as Exhibit
99.1.
The information
contained under Item 2.02 in this Current Report shall not be
deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or
incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such a filing.
|
|
|
|
|
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
The following exhibit is
filed herewith:
Exhibit
No.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
|
|
|
|
|
|
CHAMPIONS
ONCOLOGY, INC.
|
|
|
|
(Registrant)
|
|
|
|
|
|
September 14,
2020
|
By:
|
/s/ Ronnie
Morris
|
|
|
|
|
Ronnie Morris
|
|
|
|
|
Chief Executive
Officer
|
|
